MIR Stock Analysis: Mirion Technologies | NYSE
Specialty Industrial Machinery | NYSE, USA | Market Cap: 4.252m USD | 12M Return: -18.7% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 68.0M
EPS Trend: 4.4%
Qual. Beats: 0
Rev. Trend: 98.5%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 5.8 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Mirion Technologies, Inc. (NYSE: MIR) is a provider of radiation detection, measurement, analysis, and monitoring products and services, operating across North America, Europe, and the Asia Pacific. The company reports through two business segments: Medical, which supplies radiation oncology quality assurance, dosimetry, patient safety, and radionuclide therapy products used in cancer care and medical imaging; and Nuclear & Safety, which delivers personal radiation detection, identification equipment, and analytical tools for radiation safety and measurement applications.
The companys customer base spans a wide range of end markets, including hospitals, clinics, dental and veterinary offices, radiation treatment facilities, laboratories, military organizations, government agencies, industrial companies, power and utility companies, and nuclear power plants (NPPs). It also offers radiation monitoring solutions, reactor instrumentation and control detectors, imaging systems, waste management systems, and laboratory/scientific analysis systems such as gamma/alpha spectroscopy and alpha/beta counting instruments.
Mirion is classified within the Industrials sector under the Industrial Machinery & Supplies & Components sub-industry, reflecting its equipment-focused business model serving both healthcare and nuclear/industrial safety markets. The company was incorporated in 2005, is headquartered in Atlanta, Georgia, and previously operated under the name Global Monitoring Systems, Inc. before adopting its current name in January 2006. It has been publicly traded since its 2020 IPO.
- Nuclear & Safety backlog expands on global reactor new-build momentum
- Medical segment margins grow with dosimetry pricing and oncology adoption
- Defense and government radiation detection awards lift Nuclear & Safety revenue
| Net Income: 25.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.03 > 0.02 and ΔFCF/TA -0.67 > 1.0 |
| NWC/Revenue: 62.35% < 20% (prev 37.37%; Δ 24.98% < -1%) |
| CFO/TA 0.04 > 3% & CFO 127.1m > Net Income 25.1m |
| Net Debt (862.2m) to EBITDA (200.8m): 4.29 < 3 |
| Current Ratio: 3.19 > 1.5 & < 3 |
| Outstanding Shares: last quarter (244.7m) vs 12m ago 7.82% < -2% |
| Gross Margin: 47.05% > 18% (prev 47.21%; Δ -0.15% > 0.5%) |
| Asset Turnover: 31.84% > 50% (prev 33.14%; Δ -1.30% > 0%) |
| Interest Coverage Ratio: 1.46 > 6 (EBIT TTM 55.7m / Interest Expense TTM 38.1m) |
| A: 0.17 (Total Current Assets 890.9m - Total Current Liabilities 279.2m) / Total Assets 3.54b |
| B: -0.15 (Retained Earnings -516.1m / Total Assets 3.54b) |
| C: 0.02 (EBIT TTM 55.7m / Avg Total Assets 3.08b) |
| D: 1.12 (Book Value of Equity 1.84b / Total Liabilities 1.65b) |
| Altman-Z'' = 1.95 = BBB |
| DSRI: 1.15 (Receivables 295.0m/226.9m, Revenue 981.0m/870.2m) |
| GMI: 1.00 (GM 47.21% / 47.05%) |
| AQI: 0.98 (AQ_t 0.70 / AQ_t-1 0.71) |
| SGI: 1.13 (Revenue 981.0m / 870.2m) |
| TATA: -0.03 (NI 25.1m - CFO 127.1m) / TA 3.54b) |
| Beneish M = -2.82 (Cap -4..+1) = A |
As of July 09, 2026, the stock is trading at USD 16.44 with a total of 4,368,417 shares traded. Over the past week, the price has changed by -8.31%, over one month by -4.75%, over three months by -18.37% and over the past year by -18.69%.
Current recommended Stop Loss: 15.30 (which is 6.9% or 1.2 ATR below the current price).
Mirion Technologies has received a consensus analysts rating of 4.60. Therefore, it is recommended to buy MIR.
- StrongBuy: 3
- Buy: 2
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 27.9 | 69.7% |
P/E Trailing = 173.8
P/S = 4.3345
P/B = 2.3131
Revenue TTM = 981.0m USD
EBIT TTM = 55.7m USD
EBITDA TTM = 200.8m USD
Long Term Debt = 1.20b USD (from longTermDebt, last quarter)
Short Term Debt = 9.30m USD (from shortTermDebt, last quarter)
Debt = 1.27b USD (from shortLongTermDebtTotal, last quarter) + Leases 33.2m
Net Debt = 862.2m USD (calculated: Debt 1.27b - CCE 404.9m)
Enterprise Value = 5.11b USD (4.25b + Debt 1.27b - CCE 404.9m)
Interest Coverage Ratio = 1.46 (Ebit TTM 55.7m / Interest Expense TTM 38.1m)
EV/FCF = 57.02x (Enterprise Value 5.11b / FCF TTM 89.7m)
FCF Yield = 1.75% (FCF TTM 89.7m / Enterprise Value 5.11b)
FCF Margin = 9.14% (FCF TTM 89.7m / Revenue TTM 981.0m)
Net Margin = 2.56% (Net Income TTM 25.1m / Revenue TTM 981.0m)
Gross Margin = 47.05% ((Revenue TTM 981.0m - Cost of Revenue TTM 519.4m) / Revenue TTM)
Gross Margin QoQ = 46.23% (prev 48.77%)
Tobins Q-Ratio = 1.45 (Enterprise Value 5.11b / Total Assets 3.54b)
Interest Expense / Debt = 3.01% (Interest Expense 38.1m / Debt 1.27b)
Taxrate = 3.35% (900k / 26.9m)
NOPAT = 53.8m (EBIT 55.7m * (1 - 3.35%))
Current Ratio = 3.19 (Total Current Assets 890.9m / Total Current Liabilities 279.2m)
Debt / Equity = 0.69 (Debt 1.27b / totalStockholderEquity, last quarter 1.84b)
Debt / EBITDA = 4.29 (Net Debt 862.2m / EBITDA 200.8m)
Debt / FCF = 9.61 (Net Debt 862.2m / FCF TTM 89.7m)
Total Stockholder Equity = 1.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.81% (Net Income 25.1m / Total Assets 3.54b)
RoE = 1.43% (Net Income TTM 25.1m / Total Stockholder Equity 1.75b)
RoCE = 1.89% (EBIT 55.7m / Capital Employed (Equity 1.75b + L.T.Debt 1.20b))
RoIC = 1.67% (NOPAT 53.8m / Invested Capital 3.22b)
WACC = 10.45% (E(4.25b)/V(5.52b) * Re(12.70%) + D(1.27b)/V(5.52b) * Rd(3.01%) * (1-Tc(0.03)))
Discount Rate = 12.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 86.67 | Cagr: 9.55%
[DCF] Terminal Value 69.42% ; FCFF base≈87.5m ; Y1≈92.6m ; Y5≈109.0m
[DCF] Fair Price = 1.51 (EV 1.23b - Net Debt 862.2m = Equity 369.3m / Shares 244.7m; r=10.45% [WACC]; 5y FCF grow 6.53% → 2.50% )
EPS Correlation: 4.35 | EPS CAGR: 0.48% | SUE: 0.33 | # QB: 0
Revenue Correlation: 98.53 | Revenue CAGR: 8.38% | SUE: 3.17 | # QB: 1
EPS current Quarter (2026-06-30): EPS=0.10 | Chg30d=-2.38% | Revisions=-70% | Analysts=8
EPS next Quarter (2026-09-30): EPS=0.12 | Chg30d=+1.06% | Revisions=-29% | Analysts=8
EPS current Year (2026-12-31): EPS=0.54 | Chg30d=+0.00% | Revisions=-50% | GrowthEPS=+17.0% | GrowthRev=+23.0%
EPS next Year (2027-12-31): EPS=0.65 | Chg30d=+0.00% | Revisions=-57% | GrowthEPS=+21.5% | GrowthRev=+7.6%
[Analyst] Revisions Ratio: -72% (up=2, down=20)